Filing Details

Accession Number:
0001595585-19-000123
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-07-05 16:56:28
Reporting Period:
2019-07-03
Accepted Time:
2019-07-05 16:56:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1595585 Tricida Inc. TCDA Pharmaceutical Preparations (2834) 463372526
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1744280 I Sandra Coufal 7000 Shoreline Court
Suite 201
South San Francisco CA 94080
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-07-03 4,000 $37.03 11,725 No 4 S Indirect By Coufal Irrevocable Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By Coufal Irrevocable Trust
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 893,292 Indirect By Sibling Capital Fund II-A L.P.
Common Stock 3,139,600 Indirect By Sibling Capital Fund II-B L.P.
Common Stock 1,810,195 Indirect By Sibling Capital Fund II-C L.P.
Common Stock 599,379 Indirect By Sibling Capital Fund II-D L.P.
Common Stock 463,158 Indirect By Sibling Insiders Fund II L.P.
Common Stock 219,078 Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person's trust on November 17, 2018.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.03 to $38.95, inclusive. The reporting person undertakes to provide to Tricida, Inc., any security holder of Tricida, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
  3. The spouse of the Reporting Person is the sole trustee of the Coufal Irrevocable Trust. The Reporting Person disclaims beneficial ownership of the shares held by the Coufal Irrevocable Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
  4. The Reporting Person is co-manager of SCV, SCV II, SCV III, SCV IV and Sibling Insiders LLC and, as such, may be deemed to have voting and investment power with respect to the shares held by the Sibling Funds. The Reporting Person disclaims beneficial ownership of shares held by the Sibling Funds, except to the extent of her proportionate pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
  5. The shares are held directly by Sibling Capital Fund II-A L.P. ("Sibling A"). SCV is the sole general partner of Sibling A.
  6. The shares are held directly by Sibling Capital Fund II-B L.P. ("Sibling B"). Sibling Capital Ventures II LLC ("SCV II") is the sole general partner of Sibling B.
  7. The shares are held directly by Sibling Capital Fund II-C L.P. ("Sibling C"). Sibling Capital Ventures III LLC ("SCV III") is the sole general partner of Sibling C.
  8. The shares are held directly by Sibling Capital Fund II-D L.P. ("Sibling D"). Sibling Capital Ventures IV LLC ("SCV IV") is the sole general partner of Sibling D.
  9. The shares are held directly by Sibling Insiders Fund II L.P. ("Sibling Insiders Fund", and together with Sibling A, Sibling B, Sibling C and Sibling D, the "Sibling Funds"). Sibling Insiders II LLC ("Sibling Insiders LLC") is the sole general partner of Sibling Insiders Fund.
  10. Includes 1,879 restricted stock units ("RSUs") that vest on the earlier of (i) the one-year anniversary of May 31, 2019 (the "Grant Date") and (ii) the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date (the "Next Annual Meeting"), subject to the Reporting Person's continuous service as a non-employee director through such vesting date. Each RSU represents a contingent right to receive one share of Common Stock.